In stark contrast, genetic deletion of the sole inhibitory antibody checkpoint FcγRIIB fundamentally enhances in vivo therapeutic activity of cancer cell direct-targeting antibodies, including those specific for CD20, Her2, and EGFR i.e., clinically validated targets in therapy of hematologic malignancy as well as solid cancer (63). Here, EGFR is linked to cancer.